Jayme Etzel
Principal Analyst, Revenue Management
Expertise:
Jayme began her career as a corporate trainer for large manufacturers, where she developed a strong foundation in instructional design and workforce development. In 2020, she transitioned into Government Pricing and quickly developed a deep appreciation for the complexities of pharmaceutical regulations and compliance.
A passionate advocate for continuous learning, Jayme is known for sharing knowledge generously with teammates and clients alike. Since joining EVERSANA in 2025, she has already taken the initiative in designing new training programs to support the growth of emerging Government Pricing professionals.
Jayme holds a Bachelor of Science in Business Administration and continues to build on that foundation through hands-on experience and ongoing professional development.
Articles by Jayme Etzel
2026 CMS Proposed Rule: BFSF Changes and Potential Risks for Pharma Manufacturers
CMS released its 2026 Proposed Rule this summer, outlining payment and coverage policy updates for Medicare Part B and related programs. For pharmaceutical manufacturers, the most significant development is the long-awaited clarification on bona fide service fees (BFSFs). If finalized, these provisions will place new compliance demands on manufacturers. Although primarily focused on Average Sales […]
Navigating OBBBA: Why a Strong GP Team is Essential for Pharma Compliance
On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was signed into law, marking a significant shift in Medicaid, Medicare, and federal drug pricing policy. While broad in scope, its provisions have direct consequences for pharmaceutical manufacturers—especially those participating in government programs. Looking at only a few of these new regulation shifts, it becomes […]